Tran et al., 2012 - Google Patents
Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and childrenTran et al., 2012
View PDF- Document ID
- 5279490700611138005
- Author
- Tran N
- Luong C
- Vu T
- Forrat R
- Lang J
- Vu Q
- Bouckenooghe A
- Wartel T
- Publication year
- Publication venue
- J Vaccines Vaccin
External Links
Snippet
Abstract Background: Dengue viruses (DENV1-4) are estimated to infect 50-100 million individuals per year worldwide including an estimated 500,000 people with severe dengue who require hospitalization every year. The live, attenuated, tetravalent dengue vaccine …
- 206010012310 Dengue fever 0 title abstract description 154
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tran et al. | Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children | |
| Lanata et al. | Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru | |
| Capeding et al. | Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines | |
| Poo et al. | Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity | |
| Simasathien et al. | Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children | |
| Guy et al. | Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward | |
| Sabchareon et al. | Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial | |
| Timiryasova et al. | Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development | |
| Feroldi et al. | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: randomized, controlled phase 3 immunogenicity and safety trial | |
| Dayan et al. | Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil | |
| Durbin et al. | A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial | |
| Dayan et al. | Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA | |
| da Costa et al. | Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials | |
| Watanaveeradej et al. | Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial | |
| Lam et al. | Dengue vaccine–induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies | |
| Javelle et al. | Measles, the need for a paradigm shift | |
| JP2017526689A (en) | Vaccine composition against dengue virus disease | |
| Feroldi et al. | Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children | |
| Yang et al. | Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus | |
| US20230338504A1 (en) | Compositions for Booster Vaccination Against Dengue | |
| Capeding et al. | Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period | |
| Tang et al. | An epitope-substituted DNA vaccine improves safety and immunogenicity against dengue virus type 2 | |
| Zhao et al. | Low titers of measles antibody in mothers whose infants suffered from measles before eligible age for measles vaccination | |
| Sjatha et al. | Comparison of infection-neutralizing and-enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice | |
| Valdés et al. | Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates? |